Patrick Dolder
Clinical Psychopharmacologist
Data updated
Research Footprint
Patrick Dolder appears in 26 tracked papers (2015–2024), most studied alongside LSD, MDMA and Placebo, across Healthy Volunteers, Anxiety Disorders and Depressive Disorders.
Most-cited paper: Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness A randomized, double-blind, placebo-controlled Phase II study (285 citations).
Frequent co-authors: Matthias Liechti, Stefan Borgwardt and Yasmin Schmid.
Publication Landscape
How the 26 papers Blossom tracks for Patrick Dolder line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Patrick Dolder's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 26 of 26 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Patrick Dolder publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Patrick Dolder publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Patrick C. Dolder is a clinical psychopharmacology researcher known for conducting rigorous, placebo‑controlled experimental studies in healthy volunteers to map the acute effects and pharmacokinetics of lysergic acid diethylamide (LSD) and related psychoactive drugs. He has frequently collaborated with established psychopharmacology groups in Switzerland and Europe, contributing to work that uses double‑blind designs, pharmacokinetic sampling, psychometric assessment and neuroimaging to examine dose–response relationships and safety profiles.
Dolder's publications span dose‑dependent characterisations of LSD, investigations of low (micro) doses and their behavioural and subjective effects, and studies probing biological correlates such as circulating steroid levels and response‑inhibition neural networks. He has also contributed to comparative studies of stimulants and entactogens on emotion processing and to observational research on self‑reported microdosing. His work has informed clinical and basic understanding of acute psychedelic effects, methodological standards for human experimental paradigms, and the emerging dialogue on microdosing and therapeutic potential while emphasising careful pharmacological characterisation and safety monitoring.
Key Impact
Notable for leading and co‑authoring multiple human experimental studies that characterise the acute pharmacology, subjective effects and neurobiological correlates of LSD and other psychoactive compounds.
Collaboration Network
25 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Patrick Dolder's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Patrick Dolder is associated with.